ArticleGynecologic oncology reports2026
Evaluation of anaphylactic reactions involving carboplatin and paclitaxel reported to the FDA from 1970 to 2023.
Article in Gynecologic oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Acute hypersensitivity reactions to paclitaxel polymeric micelles during malignant tumor treatment: a retrospective real-world study.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Anaphylaxis to carboplatin and paclitaxel are important and potentially life-threatening events that can disrupt chemotherapeutic treatment of gynecologic cancers. Using the FDA Adverse Event Report System (FAERS), we sought to establish the relative incidence of reports of anaphylactic reactions to these drugs compared to other drugs and identify potential associations with age and sex. Methods: Using the search terms "anaphylactic reaction", "anaphylactic shock", "anaphylactoid reaction", or "anaphylactoid shock", we searched FAERS for reports associated with carboplatin or paclitaxel from 1970 until October 2023. Fatal and non-fatal reactions were included. Linear regression evaluated trends in reported cases. Results: Of 84,702 anaphylactic events reported to the FDA during the study period, 4,988 (5.9%) were fatal. Carboplatin (1,245 reports) and paclitaxel (1,430 reports) ranked 14th and 9th among all drugs associated with anaphylaxis, and 10th and 3rd among those associated with fatal anaphylaxis (8.0% and 10.6% fatality, respectively). Most reactions occurred in adults aged 18-85 (carboplatin 79.0%; paclitaxel 83.7%), and the majority of affected patients were women (carboplatin 70.4%; paclitaxel 68.8%). From 2013 to 2022, yearly anaphylactic reaction means were 77.9 total and 6.6 fatal carboplatin reports (fatal ratio 0.08), and 84.4 total and 8.2 fatal paclitaxel reports (fatal ratio 0.10). Conclusion: The ratio of fatal to total anaphylactic events remained steady over the last decade, suggesting a fatality rate of 8-10% among reports. Additional research is needed to identify biomarkers and improve management of these reactions in gynecologic oncology patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.